Precigen, Inc. (PGEN) Stock Price & Analysis
Precigen, Inc. (PGEN) closed at USD 7.2 on Thursday, October 15, 2026, down 2.18% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.36; the Oct 15, 2026 session ranged USD 7.17–7.55 on volume of 3,949,438 shares. Market capitalization is $2.58B, with a 52-week range of USD 3.04–8.98 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PGEN.md
Key facts (PGEN)
- 1 of 80 tracked superinvestors hold PGEN (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 13.65 (range 11–17.95).
- Total return with dividends: 1Y +106.3% vs S&P 500 +18.1%; 5Y +54.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD 0.08, revenue estimate $72.3M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PGEN)
| USD | FY2021 | FY2022 | FY2025 | FY2025 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M | — |
| Operating income | — | — | -$99.8M | -$135M | -$111M | — |
| Net income | -$92.2M | $28.3M | -$95.9M | -$126M | -$251M | -$158M |
| EPS (diluted) | -$0.47 | $0.14 | -$0.39 | -$0.47 | -$1.37 | — |
| Free cash flow | -$63.0M | -$70.0M | -$68.5M | -$76.8M | -$89.8M | -$115M |
| Operating margin | — | — | -1602.5% | -3440.2% | -1141.1% | — |
| Net margin | -646.0% | 105.2% | -1540.6% | -3216.2% | -2588.2% | — |
| Revenue growth | -55.4% | +88.6% | -76.9% | -36.9% | +146.7% | — |
| Cash + short-term investments | $109M | $56.0M | $62.9M | $97.9M | $100M | — |
| Total debt | $180M | $43.2M | — | $0K | $93.2M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PGEN)
P/B 59.1x · FCF yield -4.47% · Earnings yield -6.12% · Net debt $55.2M · EV $2.63B
Superinvestors (SEC 13F-HR, Q2 2026) (PGEN)
1 of 80 tracked investors hold PGEN. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Samantha McLemore | Patient Capital Management | 3.61% | $109M | Added +6.8% |
Analysts (PGEN)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 13.65 (low 11, high 17.95).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-25 | B. Riley Securities | Initiated | Buy | $12 |
| 2026-08-05 | HC Wainwright & Co. | Target raised | Buy | $14 → $18 |
| 2026-08-03 | HC Wainwright & Co. | Reiterated | Buy | $14 |
Total return (dividends reinvested) (PGEN)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +106.3% | +54.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +106.8% | +9.1% |
| Volatility (annualized) | 77.4% | 82.0% |
| Max drawdown | -40.5% (Feb 2026→Mar 2026) | -86.7% (Nov 2021→Dec 2024) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 7.2 |
|---|---|
| Change | ▼ 2.18% (down) |
| Previous Close | USD 7.36 |
| Open | USD 7.31 |
| Day Range | USD 7.17 – 7.55 |
| 52-Week Range | USD 3.04 – 8.98 |
| Volume | 3,949,438 shares |
| Market Cap | $2.58B |
| Exchange | NMS |
Technical Analysis (PGEN)
Nexqual's technical model rates PGEN "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 43.63 (neutral) |
| vs SMA50 | Below (USD 7.31) |
| MACD | 0.06 (positive) |
Analyst Ratings (PGEN)
Wall Street analysts rate PGEN "Buy" based on 4 analysts, with a mean price target of USD 13.65 (range USD 11–17.95), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 13.65 |
| High Target | USD 17.95 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (PGEN)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $72.31M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.05 vs est -0.01 ▲ beat |
| 2026-03-31 | USD -0.02 vs est -0.04 ▲ beat |
| 2025-12-31 | USD -0.01 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -1.06 vs est -0.1 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (PGEN)
| Total Revenue | $85.72M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +6322.70% |
| Gross Margin | +53.01% |
| Operating Margin | +41.18% |
| Profit Margin | -183.98% |
| ROE | -837.07% |
| Debt / Equity | 2.26 |
| Current Ratio | 4.58 |
| Total Cash | $38.21M |
| Total Debt | $98.34M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$89.83M (-927.6% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (PGEN)
Nexqual rates Precigen, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +147% YoY (annual) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $38M cash vs $98M debt |
| Cash Flow | Weak — FCF negative: -$90M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -837%, ROA -18.1% |
Ownership (PGEN)
| Insider Ownership | +12.64% |
|---|---|
| Institutional Ownership | +73.06% |
| Shares Outstanding | 358.04M |
| Float | 194.60M |
| Short % of Float | +24.36% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (PGEN)
Precigen, Inc. is led by Helen Sabzevari MPH (age 63), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO & Director | Helen Sabzevari MPH (age 63) |
|---|---|
| Executive Chairman | Randal J. Kirk (age 72) |
| Chief Financial Officer | Harry Thomasian (age 63) |
| Chief Operating Officer | Rutul R. Shah (age 44) |
Major Backers & Investors (PGEN)
Notable institutional backers of Precigen, Inc. include Patient Capital Management, LLC, Advisor Managed Portfolios-Patient Opportunity Trust, Diametric Capital, Lp, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Patient Capital Management, LLC | 5.34% |
| Advisor Managed Portfolios-Patient Opportunity Trust | 3.62% |
| Diametric Capital, Lp | 2.6% |
| Tang Capital Management, LLC | 1.8% |
| Boxer Capital Management, LLC | 1.44% |
| Iridian Asset Management LLC | 1.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.02% |
| State Street | 4.96% |
| Vanguard Group | 4.39% |
| Geode Capital | 1.41% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt